JCMS


Subject Index
AA. See Alopecia areata
Acne
   i s o t retinoin in, 66–70, S1.5– S1.10
   t reatment and scarring pre v e n-tion, S1.2–S1.10
Acquired cutis laxa, 42
Acquired perforating dermatosis, 17
Actinic prurigo, 226 ALA. See
Aminolevulinic acid Albinism, 149–152
Alexandrite laser, 83–88
A l l e rgic contact hypersensitivity, 132– 136
Alopecia in Vogt-Koyanagi-Harada dis-ease, 155–159 See also Alopecia areata
Alopecia areata (AA) cytomegalovirus in, 63–65 follicular keratinocytes in, 228– 229 Aminolevulinic acid (ALA), 227–228
Anetoderma, 42
A n t i - t r a n s f o rming growth factor-b2,3, 126–131
Apoptosis, 2–6, 227–228 ATP2A2 gene, 103–105
Beetle-bite necrosis, 219–222
Benzoyl peroxide, 138–140
Bioinformatics, 168–172
Book reviews, 173–175
Breast disease, 208–211
Calciphylaxis, 213–217
Calcipotriene, 121–125
Canadian Society for Investigative D e rmatology abstracts, 226–229
Carcinoma, 186–190
Cellular stress response, 229 Chronic urticaria, 57, 89–93 CHS. See Contact hypersensitivity Cicatricial pemphigoid, 205–207
Circumcision, 177–179
Contact hypersensitivity (CHS), 132– 136
Corticosteroids, 121–125
Cutaneous malignant melanoma, 58– 61
Cutaneous reactions, 163–166
Cutis laxa, 42
Cyclosporine, 227
Cytokines, 228–229
Cytomegalovirus, 63–65
Darier-White disease, 103–105
Dermatitis claims, 117–120
Dermatosis, 17
Diabetes, 45–48
Diphtheria antitoxin, 223–225
DNA, 2–6
Elastofibroma, 42
Elastolysis, 40–44
Elastosis perforans serpiginosa, 16– 17, 42
End-stage renal disease (ESRD), 213– 217
Epidermal necrolysis, 96–101, 227
Epidermal nevus, 30–34 ESRD.
See End-stage renal disease Feet, 45–48
Fl ashl amp-pumped pul sed dye (FLPD) laser, 36–39 FLPD.
S e e Flashlamp-pumped pulsed dye (FLPD) laser Flurandrenolide tape, 196–197
Follicular keratinocytes, 228–229
Folliculitis, 18
Fungoides, 142–147
Genital sarcoidosis, 202–204
Hair removal, 83–88
See also Alopecia Head lice resistance to over- t h e - c o u n t e r products, 199–200 scanning electron microscopy of, 181–184
Health-related quality of life, 45–48
Horse serum, 223–225
Hypersensitivity, 132–136
Hypopigmented mycosis fungoides, 142–147
Imiquimod, 76–81
I n d i rect immunofluorescence, 205– 207
Isotretinoin, 66–70
Jurkat cells, 227–228
Keratinocytes, 2–6, 228–229
Keratosis follicularis. S e e D a r i e r-White disease Kyrle’s disease, 17–18
Lamotrigine, 228
Lasers alexandrite, 83–88 pulsed dye, 36–39
Leg veins, 8–11, 62
Leprosy, 26–29
Lesions, 202–204
Lice. See Head lice Lichen planopilaris, 30–34
Lipogenesis, 138–140
Male breast, 208–211
Malignant melanoma, 58–61, 149– 152
MCC. See Merkel cell carcinoma
MCV. See Molluscum contagiosum virus Medical research, 168–172
Melanocytic nevi, 58–61 		Melanoma, 58–61, 149–152
Merkel cell carcinoma (MCC), 186– 190
Mid-dermal elastolysis, 40–44 Mol l uscum contagi os um vi ru s (MCV), 76–81
Mycobacterium leprae, 26–29
Mycosis fungoides, 142–147
Necrectomy, 219–222
Necrolysis, 96–101, 227
Necrosis, 219–222
Neonatal circumcision, 177–179
Oculocutaneous albinism, 149–152
Olanzapine, 160–162
Ontario Workplace Safety and Insur-ance Board, 117–120
Oral erosive disease, 205–207 p 33ING1 , 229 p 53 , 229
Paget’s disease, 208–211
Papular lesions, 202–204 PDT. See Photodynamic therapy Pediculosis capitis. See Head lice
Pediculus humanus capitis, 181–184, 199–200
Pemphigoid, 205–207
Penis, 202–204
Perforating dermatosis, 17
Perforating disorders, 16–18
Perforating folliculitis, 18
Perforating verrucous collagenoma, 17
Photodynamic therapy (PDT), 227– 228
Phototherapy, 196–197
Physician reimbursement, 12–15
Phytonadione. See Vitamin K 1
Pigs, 126–131
Port-wine stain, 36–39
Profore™ bandage system, 8–11, 62
Prurigo, 226
Pseudoxanthoma elasticum, 42
Psoriasis cost of treatment, 121–125 f l u r a n d renolide tape for, 196–197 gene, 226
Updike on, 113–115
Pulsed dye laser, 36–39
Pyoderma gangrenosum, 107–109
Quality of life, 45–48
Radical necrectomy, 219–222
Reactive perforating collagenosis, 17
Renal disease, 213–217
Research, 168–172
Retinoic acid, 2–6
Rheumatic disease, 26–29
Sarcoidosis, 202–204
Scanning electron microscopy (SEM), 181–184
Scarring, S1.6–S1.8, 126–131
Scrotum, 202–204
Sebaceous gland lipogenesis, 138–140
Self-mutilation, 160–162 SEM. S e e Scanni ng el ectr o n microscopy
Sensitivity, 19
Serum sickness, 223–225
Sιzary syndrome, 226–227
Skin cancer, 2–6, 186–190 diseases, 168–172 tumors, 228 See also specific conditions
Soft-tissue necrosis, 219–222
Solar elastosis, 42
Specificity, 19
Sporotrichosis, 51–54
Sterile conditions, 177–179
Stevens-Johnson syndrome, 227 T-cell receptor (TCR) gene, 142–147
TCR gene. See T-cell receptor (TCR) gene
Telemedicine, 71–74
TEN. See Toxic epidermal necrolysis
Test results, interpretation of, 19–25
T G F -b2. S e e Tr a n s f o rming gro w t h factor-b2
Thrombocythemia, 107–109
Tinea capitis, 153–154
Toluidine blue, 227
Toxic epidermal necrolysis (TEN), 96–101, 227
Tr a n s f o rming growth factor-ί2 (TGF-ί2), 126–131
Trichophyton rubrum, 153–154
Tumors, 228
Ultraviolet (UV) light, 196–197, 228
Updike, John, 113–115
Urticaria, 57, 89–95
UV light. See Ultraviolet (UV) light
VAS972 therapy, 132–136
Vascular lesions, 36–39
Veins, 8–11, 62
Vitamin K 1 , 163–166
VKH disease. S e e Vo g t - K o y a n a g i -Harada (VKH) disease Vogt-Koyanagi-Harada (VKH) dis-ease, 155–159
WCD. See Weber-Christian disease We b e r-Christian disease (WCD), 110–112
Wrinkling, 40–44

 

JCMS 4(4) Contents